CHICAGO, July 20, 2015 – New research reported in The Journal of Pain, published by the American Pain Society (www.americanpainsociety.org) shows that inhaled cannabis reduces diabetic neuropathy and the analgesic effect is dose-dependent. This neuronal damage leads to sensory disturbances, including allodynia and hyperalgesia. Many growth factors have been suggested as useful treatments for prevention of neurodegeneration, including the vascular endothelial growth factor (VEGF) family. However, its therapeutic efficacy remains unclear (5). CoQ10 treatment decreased pain hypersensitivity and long-term supplementation prevented the development of diabetic neuropathic pain but did not attenuate diabetes. Hyperalgesia and allodynia were assessed by the withdrawal responses to pressure, radiant heat, and von Frey filaments applied to the hindpaw. Moreover, the increase in phospho-p38 MAPK was significantly inhibited by intrathecal administration of losartan.